CIP2A expression in Bortezomib-treated multiple myeloma

This study aimed to investigate the expression and the prognostic value of CIP2A in multiple myeloma (MM).

The expression levels of CIP2A was measured in 33 newly diagnosed MM patients (at presentation and after 4 cycles of Bortezomib-Dexamethazone (BD) regimen) and 15 healthy controls by real time quantitative polymerase chain reaction (QRT-PCR).

CIP2A expression was upregu¬lated in MM patients compared to controls. There was a significant reduction in CIP2A expression after treatment with BD regimen. Patients with expression levels ≤ 16.45 EU (expression unit) were more likely to respond to BD regimen (23 patients out of 23) than those with expression level >16.45 (6 patients out of 10) (p=0.005). Lower progression-free survival (PFS) (16.7%) was observed among patients with high CIP2A expression levels compared to 50% PFS in patients with lower CIP2A expression levels (p=0.006).

CIP2A is upregulated in MM and bortezomib downregulated its expression. High CIP2A level is associated with shorter PFS and poor response to BD in MM. Therefore, beside its value as a poor prognostic indicator in MM, CIP2A suppression might be a fruitful future targeted therapeutic agent aiming to improve the outcome in MM.